Work

CEBPB and Itraconazole Synergistically Suppress Esophageal Squamous Cell Carcinoma Growth and Overcome Cisplatin Drug Resistance

Year: 2026
Type: preprint
Abstract: Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer in East Asia and is associated with high cancer-related mortality. CCAAT/enhancer-binding protein beta (CEBPB) is implicated in tumor progression and chemoresistance; however, its functional role and therapeutic potential in ESCC remain poorly understood. This study aimed to investigate the role of CEBPB in ESCC progression and cisplatin resistance and to explore its potential as a therapeutic target. Methods: CEBPB expression and its clinical significance were evaluated using public datasets and human ESCC tissue arrays. A human reflux model, esophageal organoids, and ESCC cell lines were used to investigate the effects of CEBPB on epithelial proliferation, differentiation, and cisplatin sensitivity. CEBPB gain- and loss-of-function experiments, apoptosis assays, pathway gene profiling and luciferase reporter assays were performed to assess its biological functions and transcriptional activity. The effects of combined cisplatin and itraconazole treatment were evaluated in ESCC cells. Statistical analyses were performed using unpaired t-tests or one-way ANOVA, and survival was analyzed using the Kaplan–Meier method and log-rank test. Results: In non-neoplastic esophageal tissues, increased CEBPB expression was associated with reflux-induced basal cell hyperplasia. Organoid experiments demonstrated that CEBPB promoted cell proliferation while suppressing basal cell differentiation. CEBPB expression was significantly elevated during ESCC progression, and higher expression was associated with poorer overall survival (P < 0.05). In cultured ESCC cells, CEBPB enhanced cell growth and survival by directly regulating the transcription of the anti-apoptotic gene MCL1. Elevated CEBPB expression conferred resistance to cisplatin, whereas CEBPB knockdown increased apoptosis and reduced MCL1 expression in cisplatin-resistant ESCC cells. Furthermore, combined treatment with cisplatin and itraconazole promoted apoptosis in cisplatin resistant and naïve ESCC cells compared with cisplatin treatment alone. Conclusions: CEBPB promotes ESCC progression and contributes to cisplatin resistance, at least in part, through transcriptional regulation of MCL1. Targeting CEBPB in combination with cisplatin may represent a potential therapeutic strategy for overcoming chemoresistance in ESCC and may have broader relevance across multiple cancer types in which CEBPB contributes to disease progression and drug resistance.
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: green
OpenAlex ID: W7236636595
Cites:
Cited by:
Related to: 10